MaxCyte, Inc. (MXCT)

MaxCyte topped consensus on both revenue and EPS in the second fiscal quarter of 2026, reported August 12, 2026, even as sales declined year over year. Revenue fell 14.5% to about $7.3 million, but still topped expectations at $7.3 million versus a $6.5 million estimate (+12%), down from about $8.5 million a year ago. EPS of -$0.08 topped the -$0.09 estimate by $0.01 and improved 33.3% from -$0.12 a year earlier, alongside net income that narrowed 28.2% to roughly -$8.9 million (from about -$12.4 million). Profitability remained negative on an operating basis, with gross profit of around $5.6 million translating to a gross margin near 77.0%, while operating loss was about -$10.2 million and operating margin was -140.7%. Cash usage continued, with negative operating cash flow of roughly -$4.7 million, and the company repurchased about $1.5 million of stock during the quarter. Consensus for the next period calls for EPS of -$0.08 on revenue of $7.0 million.